Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18952742 | 1.00 | BTK (0.43) | BTKGAAEPHX1NFKB1NFKB2 | |
| SCHEMBL20609236 | 1.00 | BTK (0.43) | BTKGAAEPHX1NFKB1NFKB2 | |
| SCHEMBL18971047 | 1.00 | BTK (0.43) | BTKGAAEPHX1NFKB1NFKB2 | |
| SCHEMBL21385465 | 1.00 | BTK (0.43) | BTKGAAEPHX1NFKB1NFKB2 | |
| SCHEMBL21629873 | 1.00 | BTK (0.43) | BTKGAAEPHX1NFKB1NFKB2 | |
| SCHEMBL2083734 | 1.00 | BTK (0.43) | BTKGAAEPHX1NFKB1NFKB2 | |
| SCHEMBL8294985 | 0.93 | BTK (0.48) | BTKGAAEPHX1NFKB1NFKB2 | |
| SCHEMBL20325892 | 0.90 | BTK (0.43) | BTKGAAEPHX1NFKB1NFKB2 | |
| SCHEMBL28675642 | 0.90 | BTK (0.43) | BTKGAAEPHX1NFKB1NFKB2 | |
| Oxalic Acid SCHEMBL22389893 | 0.88 | EPHX1 (0.45) | BTKGAAEPHX1NFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326758-A1 | RICYCLIC HETEROARYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2025-10-23 | — | — | US | disclosed |
| US-12195470-B2 | 7-phenoxy-N-(3-azabicyclo[3.2.1]octan-8-yl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivatives and related compounds as gamma- secretase modulators for the treatment of alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2025-01-14 | — | — | US | disclosed |
| US-12084461-B2 | Bicyclic heteroaryl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2024-09-10 | — | — | US | disclosed |
| EP-4424370-A2 | 7-PHENOXY-N-(3-AZABICYCLO[3.2.1LOCTAN-8-YL)-6,7-DIHYDRO-5H-PYRROLO[1,2-B][1,2,4]TRIAZOL-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS GAMMA-SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | F. Hoffmann-La Roche AG (CH) | 2024-09-04 | — | — | EP | disclosed |
| US-12030897-B2 | Pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and application thereof | MEDSHINE DISCOVERY INC. (CN) | 2024-07-09 | — | — | US | disclosed |
| US-12030897-B2 | Pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and application thereof | MEDSHINE DISCOVERY INC. (CN) | 2024-07-09 | — | — | US | disclosed |
| EP-3894411-B1 | 7-PHENOXY-N-(3-AZABICYCLO[3.2.1]OCTAN-8-YL)-6,7-DIHYDRO-5H-PYRROLO[1,2-B][1,2,4]TRIAZOL-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS GAMMA-SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | HOFFMANN LA ROCHE (CH) | 2024-06-19 | — | — | EP | disclosed |
| EP-3846903-B1 | BICYCLIC HETEROARYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-10-25 | — | — | EP | disclosed |
| WO-2022261210-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| US-11370802-B2 | Triazolo-azepine derivatives | HOFFMANN-LA ROCHE, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-10604517-B2 | Bridged piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-10562903-B2 | Bridged piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20200031831-A1 | BRIDGED PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-01-30 | — | — | US | disclosed |
| US-20200031831-A1 | BRIDGED PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-01-30 | — | — | US | disclosed |
| WO-2019214651-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINE DERIVATIVES SERVING AS SELECTIVE HER2 INHIBITORS AND APPLICATION THEREOF | 南京明德新药研发有限公司 (CN) | 2019-11-14 | — | — | WO | disclosed |
| US-20190284191-A1 | BICYCLIC HETEROARYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-09-19 | — | — | US | disclosed |
| US-20190284191-A1 | BICYCLIC HETEROARYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-09-19 | — | — | US | disclosed |
| US-20190177329-A1 | FUSED PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-06-13 | — | — | US | disclosed |
| US-20190177329-A1 | FUSED PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-06-13 | — | — | US | disclosed |
| US-20190010156-A1 | BRIDGED PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12084461-B2 | Bicyclic heteroaryl derivatives | AR, CYP1B1, CYP1A1 | BTK 2913/4885GAA 3270/4885EPHX1 2422/4885 |
| US-20200031831-A1 | BRIDGED PIPERIDINE DERIVATIVES | PSEN1, APP, PRNP | BTK 4515/4885GAA 2795/4885EPHX1 2799/4885 |
| US-20190284191-A1 | BICYCLIC HETEROARYL DERIVATIVES | HUWE1, APP, HTT | BTK 4145/4885GAA 2628/4885EPHX1 2046/4885 |
| US-10604517-B2 | Bridged piperidine derivatives | HPGDS, APP, PSEN1 | BTK 4548/4885GAA 2071/4885EPHX1 949/4885 |
| US-12195470-B2 | 7-phenoxy-N-(3-azabicyclo[3.2.1]octan-8-yl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivatives and related compounds as gamma- secretase modulators for the treatment of alzheimer's disease | BACE1, PSEN1, APP | BTK 4360/4885GAA 688/4885EPHX1 2045/4885 |
| US-11370802-B2 | Triazolo-azepine derivatives | BACE1, APP, BACE2 | BTK 4626/4885GAA 588/4885EPHX1 1783/4885 |
| US-20190177329-A1 | FUSED PYRIMIDINE DERIVATIVES | APP, UPF1, PSEN1 | BTK 3909/4885GAA 3010/4885EPHX1 1303/4885 |
| US-20250326758-A1 | RICYCLIC HETEROARYL DERIVATIVES | AR, CYP1B1, CYP1A1 | BTK 3037/4885GAA 3318/4885EPHX1 3203/4885 |
| US-12030897-B2 | Pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and application thereof | ERBB2, EGFR, ERBB3 | BTK 156/4885GAA 2189/4885EPHX1 3794/4885 |
| US-10562903-B2 | Bridged piperidine derivatives | PTGDR, HPGDS, PSEN1 | BTK 4648/4885GAA 2631/4885EPHX1 754/4885 |
| US-20190010156-A1 | BRIDGED PIPERIDINE DERIVATIVES | PTGDR, HPGDS, PSEN1 | BTK 4648/4885GAA 2631/4885EPHX1 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.